79 related articles for article (PubMed ID: 6230054)
1. [Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].
Gan To Kagaku Ryoho; 1984 Jan; 11(1):143-9. PubMed ID: 6230054
[TBL] [Abstract][Full Text] [Related]
2. [Phase II study of FF-705 by Clinical Cooperative Study Group].
Gan To Kagaku Ryoho; 1984 Jan; 11(1):150-6. PubMed ID: 6230055
[TBL] [Abstract][Full Text] [Related]
3. [Phase I clinical study of TT-62. Research group of TT-62].
Taguchi T; Furue H; Niitani H; Ohta K; Tsukagoshi S; Wakui A; Hasegawa K; Nakao I; Ohashi Y; Tominaga T
Gan To Kagaku Ryoho; 1993 Feb; 20(2):241-6. PubMed ID: 8434962
[TBL] [Abstract][Full Text] [Related]
4. Chronomodulated 5-day infusion of floxuridine and L-folinic acid in patients with advanced malignancies: a feasibility and tolerability study.
Garufi C; Lévi F; Giunta S; Aschelter A; Pace R; Nisticò C; Terzoli E
J Infus Chemother; 1995; 5(3 Suppl 1):134-7. PubMed ID: 8528973
[TBL] [Abstract][Full Text] [Related]
5. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
6. [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
Nakao I; Saito T; Kimura K; Wakui A; Yokoyama M; Kanamaru R; Furue H; Komita T; Ohta K; Murakami M
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2037-43. PubMed ID: 2932058
[TBL] [Abstract][Full Text] [Related]
7. [Phase I and pharmacokinetic study of SM-5887 by 5-day schedule].
Inoue K; Matsumura A; Horikoshi N; Aiba K; Mukaiyama T; Matsumura T; Ogihara A; Sumida T; Ogawa M
Gan To Kagaku Ryoho; 1992 Apr; 19(4):477-82. PubMed ID: 1558397
[TBL] [Abstract][Full Text] [Related]
8. [TUT-7 phase I clinical study. TUT-7 Study Group].
Taguchi T; Wakui A; Niitani H; Furue H; Majima H; Nakao I; Ota K; Hattori T; Sugimachi K
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1125-33. PubMed ID: 9239166
[TBL] [Abstract][Full Text] [Related]
9. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
13. NTP Toxicology and Carcinogenesis Studies of C.I. Direct Blue 218 (CAS No. 28407-37-6) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Feb; 430():1-280. PubMed ID: 12616301
[TBL] [Abstract][Full Text] [Related]
14. [Phase I clinical study of a new fluorinated pyrimidine antineoplastic agent, TAC-278].
Koyama Y
Gan To Kagaku Ryoho; 1982 Mar; 9(3):443-56. PubMed ID: 7184408
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
16. [Phase I clinical study of 21-consecutive-day oral administration of etoposide].
Noda K; Fukuoka M; Komatsu H; Hayashihara K; Ariyoshi Y; Tanaka K; Nakajima H; Terashima Y; Nagao K; Furuse K
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1633-9. PubMed ID: 8060139
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Jan; 424():1-304. PubMed ID: 12616287
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
20. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
